187 related articles for article (PubMed ID: 16715384)
1. Chitosan-modified dry powder formulations for pulmonary gene delivery.
Li HY; Birchall J
Pharm Res; 2006 May; 23(5):941-50. PubMed ID: 16715384
[TBL] [Abstract][Full Text] [Related]
2. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy.
Li HY; Neill H; Innocent R; Seville P; Williamson I; Birchall JC
J Drug Target; 2003 Aug; 11(7):425-32. PubMed ID: 15203931
[TBL] [Abstract][Full Text] [Related]
3. The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy.
Li HY; Seville PC; Williamson IJ; Birchall JC
J Gene Med; 2005 Aug; 7(8):1035-43. PubMed ID: 15756712
[TBL] [Abstract][Full Text] [Related]
4. Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes.
Colonna C; Conti B; Genta I; Alpar OH
Int J Pharm; 2008 Nov; 364(1):108-18. PubMed ID: 18775770
[TBL] [Abstract][Full Text] [Related]
5. Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying.
Seville PC; Kellaway IW; Birchall JC
J Gene Med; 2002; 4(4):428-37. PubMed ID: 12124985
[TBL] [Abstract][Full Text] [Related]
6. The influence of formulation components on the aerosolisation properties of spray-dried powders.
Rabbani NR; Seville PC
J Control Release; 2005 Dec; 110(1):130-40. PubMed ID: 16226334
[TBL] [Abstract][Full Text] [Related]
7. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy.
Li HY; Seville PC; Williamson IJ; Birchall JC
J Gene Med; 2005 Mar; 7(3):343-53. PubMed ID: 15515142
[TBL] [Abstract][Full Text] [Related]
8. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery.
Sinsuebpol C; Chatchawalsaisin J; Kulvanich P
Drug Des Devel Ther; 2013; 7():861-73. PubMed ID: 24039397
[TBL] [Abstract][Full Text] [Related]
9. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
10. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.
Keil TWM; Feldmann DP; Costabile G; Zhong Q; da Rocha S; Merkel OM
Eur J Pharm Biopharm; 2019 Oct; 143():61-69. PubMed ID: 31445157
[TBL] [Abstract][Full Text] [Related]
11. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
[TBL] [Abstract][Full Text] [Related]
12. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
Lucas P; Anderson K; Staniforth JN
Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
[TBL] [Abstract][Full Text] [Related]
13. Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation.
Mohri K; Okuda T; Mori A; Danjo K; Okamoto H
J Control Release; 2010 Jun; 144(2):221-6. PubMed ID: 20184930
[TBL] [Abstract][Full Text] [Related]
14. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
Thi TH; Danède F; Descamps M; Flament MP
Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
[TBL] [Abstract][Full Text] [Related]
15. The effect of operating and formulation variables on the morphology of spray-dried protein particles.
Maa YF; Costantino HR; Nguyen PA; Hsu CC
Pharm Dev Technol; 1997 Aug; 2(3):213-23. PubMed ID: 9552449
[TBL] [Abstract][Full Text] [Related]
16. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung.
Sham JO; Zhang Y; Finlay WH; Roa WH; Löbenberg R
Int J Pharm; 2004 Jan; 269(2):457-67. PubMed ID: 14706257
[TBL] [Abstract][Full Text] [Related]
17. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
18. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
Pilcer G; Sebti T; Amighi K
Pharm Res; 2006 May; 23(5):931-40. PubMed ID: 16715383
[TBL] [Abstract][Full Text] [Related]
19. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
Zeng XM; Martin GP; Marriott C; Pritchard J
J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
[TBL] [Abstract][Full Text] [Related]
20. Impact of excipient choice on the aerodynamic performance of inhalable spray-freeze-dried powders.
Wanning S; Süverkrüp R; Lamprecht A
Int J Pharm; 2020 Aug; 586():119564. PubMed ID: 32590097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
